AbbVie partners with Iambic on AI drug discovery

AbbVie announced a multi-year collaboration with clinical-stage biotechnology firm Iambic on September 21, 2026, aimed at accelerating the discovery and development of small molecule therapies. The alliance focuses on programs across immunology, neuroscience, and oncology.

The partnership will deploy Iambic's AI platform, specifically its Enchant v3 multimodal transformer model, which is trained on more than 6,000 molecular properties. The technology allows researchers to assess multiple candidate characteristics simultaneously and test drug design hypotheses in parallel.

Under the agreement, Iambic will receive an upfront payment, as well as tiered royalties on future net sales of therapies resulting from the collaboration.